Leora Horn, MD, MSc | Authors

Articles

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

August 11, 2020

Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.

Real-World Comparison Assesses Mobocertinib in NSCLC With EGFR Exon 20

July 29, 2020

Leora Horn, MD, MSc, discusses the real-world data outcomes compared with clinical trial data of mobocertinib from a retrospective study in patients with refractory non–small cell lung cancer with EGFR exon 20 insertions.